54741_Image_jpeg.jpg
Daxor’s Blood Volume Analyzer (BVA-100®) To Be Used As a Key Metric in Study of “Long Hauler” COVID-19 Patients
25 mai 2022 08h00 HE | Daxor Corporation
Oak Ridge, TN, May 25, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today participation in the National Institutes of...
54741_Image_jpeg.jpg
Daxor Corporation to Present at the H.C. Wainwright & Company Global Investment Conference
12 mai 2022 08h00 HE | Daxor Corporation
NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that President and CEO Michael Feldschuh will...
54741_Image_jpeg.jpg
New Data Validates Blood Volume Analysis Guided-Care, Improves Survival in Patients with Advanced Heart Failure Supported with Left Ventricular Assist Device
02 mai 2022 08h00 HE | Daxor Corporation
Study Presented at the International Society for Heart and Lung Transplant 42nd Annual Meeting and Scientific Sessions 2022 Oak Ridge, TN, May 02, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation...
54741_Image_jpeg.jpg
New Study from Duke Heart Demonstrates the Unique Accuracy and Utility of Daxor’s Blood Volume Diagnostic (BVA-100®) for Improving Worsening Heart Failure
06 avr. 2022 08h00 HE | Daxor Corporation
Study Presented at the 71st Annual American College of Cardiology Meeting Oak Ridge, TN, April 06, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume...
54741_Image_jpeg.jpg
Daxor Corporation to Participate in the Maxim Group 2022 Virtual Growth Conference
23 mars 2022 08h00 HE | Daxor Corporation
Oak Ridge, TN, March 23, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces that President and CEO Michael Feldschuh will...
54741_Image_jpeg.jpg
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
01 mars 2022 09h00 HE | Daxor Corporation
Oak Ridge, TN, March 01, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today issued a corporate update in a Letter to...
54741_Image_jpeg.jpg
Daxor Corporation Announces $1.35 Per Share NAV Increase and Files Annual Report for Fiscal 2021
01 mars 2022 08h00 HE | Daxor Corporation
Revenues of Operating Division Increase by 70.6% Oak Ridge, TN, March 01, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, filed...
54741_Image_jpeg.jpg
Study Demonstrates Importance and Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in the Assessment of Heart Failure
17 févr. 2022 08h00 HE | Daxor Corporation
Daxor’s BVA-100® Shown to Provide Unique and Actionable Data for Addressing Heart Failure Oak Ridge, TN, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in...
54741_Image_jpeg.jpg
Daxor Corporation Commences Trading on The NASDAQ Capital Market
02 févr. 2022 08h00 HE | Daxor Corporation
Management to Ring the Nasdaq Stock Market Opening Bell on February 4, 2022 Oak Ridge, TN, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume...
54741_Image_jpeg.jpg
Caleb DesRosiers, JD, MPA Appointed to Daxor Corporation Board of Directors
21 janv. 2022 08h00 HE | Daxor Corporation
Oak Ridge, TN, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announced today that it has appointed Caleb DesRosiers, JD,...